Stable nimodipine parenteral formulation

A directly infusible nimodipine formulation suitable for parenteral administration in humans, comprising nimodipine in a concentration from about 0.01 mg/ml to about 1.0 mg/ml, a pharmaceutically acceptable organic solventconsisting of ethanol copmrising less than 2% w/v of the formulation, a pharmaceutically acceptable aqueous carrier, and an effective amount of a single hydrophilic surfactant which is polysorbate 80 and is from 0.01% to about 2.5% w/v of the formulation, such that the nimodipine is substantially contained in micelles, the formulation comprising a volume from about 50 ml to about 1000 ml and contained in a pharmaceutically acceptable container, the formulation being a stable clear micellar solution and displaying no precipitation of nimodipine, wherein the directly infusible nimodipine injection formulation does not contain poloxamer, a phospholipid, or an oil.